BSC and Almirall to identify unprecedented target-disease associations on dermatological indications

The combination of the latest digital and omics technologies will facilitate the identification of new targets for dermatological diseases.
Almirall, S.A. and the group of Computational Genomics from the Life Sciences Department of the Barcelona Supercomputing Center (BSC), have entered into a research collaboration focused on the identification of new targets to treat dermatological diseases.
The aim of this collaboration is to identify new unprecedented target–disease associations using a number of large scale public omics data sources in combination with the unique expertise and phenomenal technological capabilities of the Barcelona Supercomputing Center (BSC). These capabilities will be used by the BSC to re-analyze existing omics datasets from two dermatological diseases within Almirall focus in order to deliver new target opportunities.

Omics refers to the collective technologies used to explore the roles, relationships, and actions of the various types of molecules and processes that make up the cells of an organism, and have been named as genomics, transcriptomics, proteomics, metabolomics, etc. depending on the family of cellular molecules and processes in each case.

**Dr. Jorge Beleta, Research Director, Almirall**, commented: “We believe that the world class expertise and capabilities of Dr. Torrents’ group at the Barcelona Supercomputing Center will provide an excellent opportunity to integrate the power of the latest digital and omics technologies into our drug discovery platform”.

At the same time, **Dr. David Torrents, leader of the Computational Group from the Barcelona Supercomputing Center**, stated: "For us, collaborating with companies such as Almirall is a great opportunity to apply our research to specific cases and to continue to improve processes and methods based on the massive analysis of data to speed up the discovery of drugs."

**About Almirall**

Almirall is a leading skin-health focused global pharmaceutical company that partners with healthcare professionals, applying Science to provide medical solutions to patients & future generations. Our efforts are focused on fighting against skin health diseases and helping people feel and look their best. We support healthcare professionals in its continuous improvement, bringing our innovative solutions where they are needed. The company, founded in 1943 and with headquarters in Barcelona, is listed on the Spanish Stock Exchange (ticker: ALM). Almirall has become a key element of value creation to society according to its commitment with its major shareholders and its decision to help others, to understand their challenges and to use Science to provide them with solutions for real life. Total revenue in 2017 was 755.8 million euros and more than 1,830 employees are devoted to Science. For more information, please visit almirall.com

Barcelona Supercomputing Center - Centro Nacional de Supercomputación